Update upon efficacy and safety of TNF-α inhibitors

Bibliography

• Peschon JJ, Torrance DS, Stocking KL, TNF receptor-defi cient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-52
   PubMed Web of Science ®Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents–a guide for GPs. Aust Fam Physician 2007;36:1035-8
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
   PubMed Web of Science ®Google Scholar
• Feagan BG, Enns R, Fedorak RN, Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 2001;8(4):188-98
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Reinisch W, SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126(6):1593-610
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc) 2011;47(1):277-88
   PubMedGoogle Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009;104(5):1170-9
   PubMed Web of Science ®Google Scholar
• Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther 2010;32:1681-703
   PubMed Web of Science ®Google Scholar
• Launois R, Avouac B, Berenbaum F, Comparison of certolizumab pegol with other Anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian Metaanalysis. J Rheumatol 2011; In press
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer AM, Bansky G, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surve. Inflamm Bowel Dis 2010; In press
   Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9(8):670-8. e3
   PubMed Web of Science ®Google Scholar
• Gisondi P, Gubinelli E, Cocuroccia B, Girolomoni G. Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:175-83
   PubMedGoogle Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Droll B, Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74
   PubMed Web of Science ®Google Scholar
• Furst DE, Breedveld FC, Kalden JR, Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005. 64(Suppl 4):iv2-14
   Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
   PubMed Web of Science ®Google Scholar
• Dallocchio A, Canioni D, Ruemmele F, SOFREMIP. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49(9):1694-8
   PubMed Web of Science ®Google Scholar
• Saunders BM, Tran S, Ruuls S, Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005;174:4852-9
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
   PubMed Web of Science ®Google Scholar